Phase II Trial Opens: AI-Guided CDK4/6 Inhibitor Rechallenge vs Physician's Choice in HR+ HER2- Advanced Breast Cancer

References

1. 1.University of California, San Diego. (2024). Artificial Intelligence and Machine Learning-Enhanced Biomarker-dRiven CDK4/6 Inhibitor Rechallenge in HR+ HER2- Advanced Breast Tumors. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07227233
2. 2.Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S. A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., Gauthier, E., Lu, D. R., Randolph, S., Diéras, V., & Slamon, D. J. (2016). Palbociclib and letrozole in advanced breast cancer. New England Journal of Medicine, 375(20), 1925-1936. https://doi.org/10.1056/NEJMoa1607303
3. 3.Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y. S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., Janni, W., Verma, S., Conte, P., Arteaga, C. L., Cameron, D. A., Petrakova, K., Hart, L. L., Villanueva, C., Chan, A., ... O'Shaughnessy, J. (2016). Ribociclib as first-line therapy for HR-positive, advanced breast cancer. New England Journal of Medicine, 375(18), 1738-1748. https://doi.org/10.1056/NEJMoa1609709
4. 4.Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M. S., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G. S., Biganzoli, L., Boyle, F., Cardoso, M. J., Carey, L. A., Cortés, J., El Saghir, N. S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P. A., ... Winer, E. P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31(12), 1623-1649. https://doi.org/10.1016/j.annonc.2020.09.010
5. 5.Wander, S. A., Cohen, O., Gong, X., Johnson, G. N., Buendia-Buendia, J. E., Lloyd, M. R., Kim, D., Luo, F., Mao, P., Helvie, K., Kowalski, K. J., Nayar, U., Buchanan, S., Langenbucher, A., Yennawar, S., Cai, S., Patel, T., Anders, L., Waks, A. G., ... Wagle, N. (2020). The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor–positive metastatic breast cancer. Cancer Discovery, 10(8), 1174-1193. https://doi.org/10.1158/2159-8290.CD-19-1390
6. 6.Li, Z., Razavi, P., Li, Q., Toy, W., Liu, B., Ping, C., Hsieh, W., Sanchez-Vega, F., Brown, D. N., Da Cruz Paula, A. F., Morris, L., Selenica, P., Eichenberger, E., Shen, R., Schultz, N., Rosen, N., Scaltriti, M., Brogi, E., Baselga, J., ... Chandarlapaty, S. (2018). Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the Hippo pathway. Cancer Cell, 34(6), 893-905. https://doi.org/10.1016/j.ccell.2018.09.006
7. 7.Therapeutic Goods Administration. (2024). Australian Register of Therapeutic Goods. Australian Government Department of Health. https://www.tga.gov.au/products/medicines/artg